Processing

Please wait...

Settings

Settings

1. WO2000043332 - BIOPOLYMERS COMPRISING HUMAN IMMUNODEFICIENCY VIRUS TAT

Publication Number WO/2000/043332
Publication Date 27.07.2000
International Application No. PCT/US2000/001957
International Filing Date 25.01.2000
Chapter 2 Demand Filed 23.08.2000
IPC
C07K 14/16 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
155Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
16HIV-1
CPC
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 2740/16322
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
16011Human Immunodeficiency Virus, HIV
16311concerning HIV regulatory proteins
16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Applicants
  • UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY [US/US]; 335 George Street Suite 3200 New Brunswick, NJ 08903-2688, US (AllExceptUS)
  • RANA, Tariq, M. [US/US]; US (UsOnly)
Inventors
  • RANA, Tariq, M.; US
Agents
  • REED, Janet, E. ; Saul, Ewing, Remick & Saul, L.L.P. Centre Square West 1500 Market Street, 38th Floor Philadelphia, PA 19102-2186, US
Priority Data
60/117,09925.01.1999US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BIOPOLYMERS COMPRISING HUMAN IMMUNODEFICIENCY VIRUS TAT
(FR) OLIGOUREA DERIVEE DE LA TAT, PROCEDE D'ELABORATION, ET UTILISATION POUR UNE LIAISON SPECIFIQUE A GRANDE AFFINITE AVEC L'ARN TAR DU VIH-1
Abstract
(EN)
This invention relates to the use of oligourea molecules to specifically inhibit protein-nucleic acid interactions. In particular, it provides an oligourea molecule that competes with the Tat molecule for the TAR RNA of HIV-1. Also provided is a method specifically inhibiting protein-nucleic and interactions, and kits.
(FR)
L'invention concerne l'utilisation de molécules d'oligouréa visant à inhiber spécifiquement les interactions protéine-acide nucléique. L'invention concerne en particulier une molécule d'oligouréa qui entre en concurrence avec la molécule Tat pour la liaison avec l'ARN TAR du VIH-1. L'invention concerne en outre un procédé qui permet d'inhiber spécifiquement les interactions protéine-acide nucléique, et des kits correspondants.
Also published as
Latest bibliographic data on file with the International Bureau